🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jacob D. Soumerai

Massachusetts General Hospital

ORCID: 0000-0002-3062-6819

Also affiliated with Global Cancer Institute, Center for Cancer Research

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings”.

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings

Frontiers in Immunology(2025)10.3389/fimmu.2024.1369619
N/A
0.343DataRank · unranked
7 citations

Camille N. Kotton, Jae‐Hyun Park, Giorgia Moranzoni, Camilla K. Lemvigh, Joseph Gathe +30 more

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood(2020)10.1182/blood.2020006288
N/A
0DataRank · unranked
340 citations

Jorge J. Castillo, Alan P Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera +3 more

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0964
N/A
0DataRank · unranked
13 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148218
N/A
0DataRank · unranked
4 citations

Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, José F. Leis +7 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596
N/A
0DataRank · unranked
0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596.v1
N/A
0DataRank · unranked
0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence

Blood Advances(2024)10.1182/bloodadvances.2024013073
N/A
0DataRank · unranked
20 citations

Zaid Yousif, Thais Gift, Raj Desai, Lynn Huynh, Mingchen Ye +11 more

Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Leukemia & lymphoma/Leukemia and lymphoma(2024)10.1080/10428194.2024.2310144
N/A
0DataRank · unranked
17 citations

Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Y. Delgado Medrano, Josie Ford +4 more

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

British Journal of Haematology(2024)10.1111/bjh.19419
N/A
0DataRank · unranked
5 citations

Catherine Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L. Tsai +11 more

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016006
N/A
0DataRank · unranked
12 citations

Yinglu Zhou, Mariia Mikhaleva, Daniel Choi, Stacey M. Fernandes, Philippe Armand +20 more

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

Blood Neoplasia(2025)10.1016/j.bneo.2025.100075
N/A
0DataRank · unranked
1 citations

Matthew Lei, Robert Redd, Ruchi Rana, Uvette Lou, Mark N Sorial +19 more

Developing MRD as an early endpoint for accelerated approval in CLL

Seminars in Hematology(2025)10.1053/j.seminhematol.2026.03.008
N/A
0DataRank · unranked
1 citations

William G. Wierda, Jacob D. Soumerai

414 | CT‐BASED BODY COMPOSITION IN PATIENTS WITH FOLLICULAR LYMPHOMA COMPARED WITH THE GENERAL POPULATION, AND ASSOCIATION BETWEEN BODY COMPOSITION AND LYMPHOMA OUTCOMES

Hematological Oncology(2025)10.1002/hon.70094_414
N/A
0DataRank · unranked
0 citations

Lea Mantz, Robert Redd, Matthew Lei, Jeremy S. Abramson, J. Barnes +14 more

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Blood Cancer Journal(2020)10.1038/s41408-020-00340-z
N/A
0DataRank · unranked
203 citations

Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying +20 more

140 | PHASE 2 TRIAL OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN COMBINATION WITH ACALABRUTINIB IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS (LBCL)

Hematological Oncology(2025)10.1002/hon.70093_140
N/A
0DataRank · unranked
0 citations

Jon Arnason, Robert Redd, J. Erika Haydu, Jacob D. Soumerai, Jeffrey A. Barnes +7 more